CureVac Converts To Modified mRNA And Stock Soars

New CEO Incoming

 
• By Kevin Grogan

CureVac, formerly a cheerleader of the unmodified mRNA approach, is embracing the modified version for its vaccine portfolio, a move that has gone down well with the investment community.

TUEBINGEN, GERMANY - NOVEMBER 21: (BILD ZEITUNG OUT) the Logo of Curevac is seen on a sign in front of the CUREVAC building on November 21, 2020 in Tuebingen, Germany.
• Source: Harry Langer/DeFodi Images via Getty Images (DeFodi Images/Getty Images)

More from Clinical Trials

More from R&D